Introduction
Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the United States, accounting for 25% of all leukemias 1 . CLL is currently an incurable disease characterized by the gradual accumulation of mature B-lymphocytes arrested in the G 0 phase of the cell cycle. CLL cells co-express mature B-cell antigens, such as CD19, CD20, and CD23, and display a typical B cell morphology. The underlying pathogenesis of the disease remains unknown, but the slow-growing CLL cells are thought to accumulate from a defect in apoptosis 2 . Current drug therapy has some activity against CLL but has minimal impact on survival. Improvement in the treatment of CLL depends upon identifying new therapeutic approaches.
One promising new drug for treating CLL is the macrocyclic lactone, Bryostatin 1, a naturally derived compound from a marine bryozoan. The antineoplastic effects of Bryostatin 1 are attributed to its ability to interact with protein kinase C (PKC). Like phorbol esters, Bryostatin 1 modulates PKC activity with a distinct pattern of activation of PKC isoforms in a highly tissue specific manner 3, 4 . Unlike phorbol esters, Bryostatin 1 does not have tumor promoting properties, which makes it an attractive therapeutic agent. Bryostatin 1 is considered both an agonist and an antagonist of PKC activity in that it binds to the diacylglycerol (DAG) binding site of PKC resulting in the activation of PKC with acute exposure and down-regulation and loss of PKC activity with chronic exposure.
Among the potent biological effects of Bryostatin 1 is the ability to induce differentiation of both myeloid and lymphoid leukemic cells [5] [6] [7] . Bryostatin 1 induces differentiation of CLL cells 8 and has antileukemic activity in vivo 9, 10 . Treatment of CLL only.
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Bryostatin 1 can also sensitize hematological tumor cells to conventional cytotoxic agents by increasing their susceptibility to apoptosis and/or further leukemic cell maturation 11 .
The observation that Bryostatin 1 has antineoplastic activity, causes differentiation of CLL cells, and can potentiate the cytotoxic activity of other drugs led to clinical trials testing Bryostatin 1 in CLL patients. Phase I and II clinical trials have demonstrated that Bryostatin 1 has the potential for the treatment of refractory acute leukemias and indolent hematological malignancies 9, [11] [12] [13] . Bryostatin 1 is currently undergoing Phase I and II analysis in combination with other chemotherapeutic agents, including fludarabine, cladribine, and vincristine, for indolent hematological malignancies including CLL.
The exact mechanism of action of Bryostatin 1 remains unclear and likely involves signaling pathways in addition to PKC to achieve the full spectrum of its biological effects. In considering signaling pathways that may be modulated by Bryostatin 1, we have focused on STAT proteins. STATs are a family of transcription factors that are key mediators of extracellular stimuli in lymphocytes 14 . Following stimulation by ligands such as cytokines, STATs are phosphorylated on tyrosine residues by Janus kinases (JAKs) and on serine residues by a variety of serine/threonine kinases.
STATs then dimerize, translocate to the nucleus and bind DNA where they initiate the transcription of target genes. Tyrosine phosphorylation is necessary for STAT dimerization, nuclear translocation, and DNA binding while serine phosphorylation is associated with enhanced transcriptional activity. Previous studies demonstrated that, in 
Materials and Methods

Cells and culture conditions
After informed consent, CLL cells were isolated from heparinized blood of untreated patients diagnosed with CLL according to clinical and immunophenotypic criteria.
Mononuclear cells were isolated by Ficoll density gradient centrifugation. Greater than 95% of Ficoll-separated cells co-expressed CD5 and CD19 as determined by flow cytometry. In some cases, purified B cells were isolated by negative selection of the separated cells using magnetic bead depletion (MACS B cell isolation kit; Miltenyi Biotech, Auburn, CA). The enriched cell population was greater than 95% CD5/CD19 positive. Fresh and cryopreserved CLL cells were studied. For studies where frozen cells were used, CLL cells were frozen in fetal bovine serum (FBS) containing 10% dimethyl sulfoxide (DMSO) and stored in liquid nitrogen. CLL cells were cultured in RPMI-1640 containing 10% FBS.
Reagents
Bryostatin 1 (NSC 339555) was obtained from the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, resuspended at a concentration of 500 µM in DMSO, and stored at -20ºC. Just prior to use, Bryostatin 1 was diluted to 5 µM in DMSO and used at a final concentration of 10 nM. AG490, Gö6850, and Gö6976 were purchased from Calbiochem (San Diego, California).
PD98059 and U0126 were purchased from Cell Signaling (Beverly, Massachusetts).
Cycloheximide was purchased from Sigma-Aldrich (St. Louis, Missouri). Anti-PKC antibodies were purchased from BD Transduction labs (San Diego, CA). Recombinant 
Western blot analysis
CLL cells were lysed in buffer containing 50 mM Tris-Cl, pH 8.0, 250 mM NaCl, 0.5% NP40, 2 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 2 µg/ml of pepstatin. For Western analysis, 80 µg of protein were resolved on 7% SDSpolyacrylamide gels and transferred to nitrocellulose membranes. Blots were incubated with an antibody specific for the tyrosine or serine phosphorylated form of STAT1 15,17 using a 1:10,000 dilution of the antibody in Tris-buffered saline/0.05% Tween 20 (TBST) for 45 minutes at room temperature. The blots were stripped and re-probed with an antibody that recognizes total STAT1 (Santa Cruz Biotechnology, Santa Cruz, CA, SC-346) using a 1:20,000 dilution of the antibody. Blots were incubated with goat anti-rabbit horseradish peroxidase-conjugated secondary antibodies (Calbiochem, La Jolla, CA) and detection was performed using the Renaissance chemiluminescent ECL kit (NEN Dupont, Boston, MA).
Nuclear extract preparation and electrophoretic mobility shift assay
Nuclear extracts were prepared by resuspending cells in hypotonic buffer (10 mM Tris, pH 7.4, 10 mM NaCl, 6 mM MgCl 2 , 1 mM -mercaptoethanol ( ME), 1 mM sodium orthovanadate, 10 µg/ml PMSF, 2 µg/ml pepstatin, 2 µg/ml leupeptin, and 10 mM aprotinin) followed by incubation on ice for 5 minutes. Cells were centrifuged for 10 seconds at 12,000 x g, resuspended in hypotonic buffer, and disrupted using a Dounce only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From homogenizer (Type B pestle, 30 strokes). The nuclei were collected by centrifugation for 10 seconds at 12,000 x g and washed once with hypotonic buffer. The nuclear pellet was resuspended in 1 pellet volume of high salt buffer (20 mM HEPES, pH 7.9, 420 mM NaCl, 1.5 mM MgCl 2 , 25% glycerol, 0.2 mM EDTA, 10 µg/ml PMSF, 1 mM sodium orthovanadate, and 1 mM ME) and incubated for 30 minutes at 4°C followed by centrifugation for 3 minutes at 12,000 x g. Two microliters of nuclear extract were incubated with a double stranded 32 
RT-PCR analysis
RNA was isolated using the RNEasy purification method (Qiagen, Valencia, CA). Five micrograms of total RNA were reverse transcribed using random primers and PCR amplified using IFN -(5'-ATGAAATATACAAGTTATATCTTGGCTTT-3' and 3'-GATGCTCTTCGACCTCGAAACAGCAT-5') or GAPDH-(5'-GAAGGTGAAGGTCGGAGTC-3' and 3'-GAAGATGGTGATGGGATTC-5') specific Viability was monitored by trypan blue exclusion and was routinely 60-80% after 24
hours of cell culture.
RNA Isolation and Microarray Analysis
CLL cells were left untreated, or treated with 10 nM Bryostatin 1 or 10 units/ml IFN (R&D Systems) for 3 hours. Total RNA was isolated using Trizol (Invitrogen Life only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From Technologies, Carlsbad, CA) and further purified using RNEasy spin columns (Qiagen, Valencia, CA). Preparation of cRNA, oligonucleotide array hybridization to HG-U133A GeneChip arrays (Affymetrix, Santa Clara, CA), and scanning of the arrays was performed by the Dana-Farber Microarray Core Facility. Data analysis was performed using the DNA-Chip Analyzer (dChip) software 18 . Gene array data were normalized, and perfect-match only model-based expression intensities were obtained in dChip. To exclude those genes that lacked sufficient variability across groups, gene filtering was also performed in dChip. The metabolic quiescence of CLL cells resulted in relatively low magnitude changes in the vast majority of genes. Therefore, to identify those genes whose expression patterns best distinguished 2 groups, we required the fold change between the group means to exceed a threshold of 1.5.
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Results
Bryostatin 1 induces activation of STAT1
To determine whether Bryostatin 1 can modulate STAT signaling, primary CLL cells were incubated with Bryostatin 1 and then analyzed for changes in STAT1 tyrosine or serine phosphorylation. Using an antibody specific for the phosphorylation of tyrosine 701, the amino acid residue necessary for activation of STAT1, Western blot analysis revealed that STAT1 was tyrosine phosphorylated within 1.5 hours after addition of Bryostatin 1 ( Figure 1A ). Bryostatin 1 had no effect on the constitutive serine phosphorylation of STAT1 in CLL cells. To confirm the ability of tyrosine phosphorylated STAT1 to bind to its cognate DNA sequence, electrophoretic mobility shift assay (EMSA) was performed using a rabdiolabeled interferon gamma activation tyrosine phosphorylation ( Figure 2C ). Therefore, STAT1 activation is dependent upon PKC activation.
Activation of STAT1 is dependent upon MAPK activation and new protein synthesis
Both Bryostatin 1 and PKC activation are known to stimulate MAPK activity [27] [28] [29] [30] . MAPK is known to be required for Bryostatin 1-induced differentiation of acute lymphoblastic leukemia cells 28 . We reasoned that MAPK and its associated downstream signaling events could be important in Bryostatin 1-induced differentiation of CLL cells. For It is worth noting that, unlike IgM production, which is detectable between 24 and 48 hours following Bryostatin 1 treatment, the kinetics of CD22 up-regulation closely follow the kinetics of STAT1 activation. STAT1 activation occurs within 1.5 hours of Bryostatin 1 treatment and is maintained through 24 hours, the time when CD22 upregulation is detectable, and returns to basal levels by 48 hours (data not shown).
Although IFN is typically produced by T lymphocytes and NK cells, it is known to be produced by malignant B cells 38 and has been shown to have either positive or negative physiological effects on CLL cells, depending on the concentration used.
Previous studies have demonstrated that IFN can protect CLL cells from apoptosis in vitro, and that serum from CLL patients contains increased levels of IFN compared to that of healthy donors, suggestive of a role for IFN in suppressing apoptosis in vivo as well [38] [39] [40] [41] . These studies used or detected much higher levels of IFN compared to the levels detected in Bryostatin 1-treated CLL cells in the present study. Thus, the level of only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From IFN needed to induce STAT1-mediated differentiation may be very low, and there may be a threshold above which IFN has anti-apoptotic effects. IFN may also have inhibitory effects on CLL cells. IFN was shown to inhibit the expression of matrix metalloproteinase 9 (MMP-9), a protease responsible for the degradation of the extracellular matrix and possibly associated with tissue infiltration of CLL cells 42 .
IFN inhibited MMP-9 expression even at very low concentrations (1 unit/ml). Thus, in addition to activating STAT1, low concentrations of IFN may have anti-angiogenic effects in CLL similar to that observed in endothelial cells 43, 44 .
Although inappropriate STAT activation is present in a number of acute and chronic leukemias and may contribute to their pathogenesis 45 hours. Whole cell lysates were prepared and analyzed by Western blotting using antibodies specific for Tyr-P-STAT1, and blots were stripped and re-probed for total STAT1. Similar results were found in experiments using 4 additional patients' cells. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From
